ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 206 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2020. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,824,820 | -32.0% | 275,591 | -12.0% | 0.00% | -50.0% |
Q2 2023 | $14,445,379 | +24.6% | 313,145 | +8.3% | 0.00% | +100.0% |
Q1 2023 | $11,591,000 | +84660.5% | 289,068 | -2.1% | 0.00% | -50.0% |
Q4 2022 | $13,675 | -99.9% | 295,155 | -5.6% | 0.00% | 0.0% |
Q3 2022 | $12,952,000 | -26.4% | 312,771 | +6.0% | 0.00% | 0.0% |
Q2 2022 | $17,598,000 | -19.5% | 294,957 | -2.1% | 0.00% | -33.3% |
Q1 2022 | $21,869,000 | -19.1% | 301,143 | -6.3% | 0.00% | 0.0% |
Q4 2021 | $27,039,000 | -3.4% | 321,554 | +3.6% | 0.00% | 0.0% |
Q3 2021 | $27,982,000 | -16.4% | 310,251 | -11.6% | 0.00% | -25.0% |
Q2 2021 | $33,460,000 | -4.1% | 350,919 | +14.5% | 0.00% | -20.0% |
Q1 2021 | $34,896,000 | +8.9% | 306,479 | +32.4% | 0.01% | 0.0% |
Q4 2020 | $32,037,000 | +102.4% | 231,430 | +24.4% | 0.01% | +66.7% |
Q3 2020 | $15,827,000 | +35.7% | 185,974 | +24.7% | 0.00% | +50.0% |
Q2 2020 | $11,664,000 | +135.0% | 149,107 | +33.5% | 0.00% | +100.0% |
Q1 2020 | $4,963,000 | +105.6% | 111,710 | +97.6% | 0.00% | – |
Q4 2019 | $2,414,000 | +166.4% | 56,524 | +167.2% | 0.00% | – |
Q3 2019 | $906,000 | -19.1% | 21,156 | +17.2% | 0.00% | – |
Q2 2019 | $1,120,000 | -16.2% | 18,049 | -6.4% | 0.00% | – |
Q1 2019 | $1,337,000 | +125.5% | 19,276 | +41.4% | 0.00% | – |
Q4 2018 | $593,000 | -40.4% | 13,631 | +4.6% | 0.00% | – |
Q3 2018 | $995,000 | -22.6% | 13,037 | -22.1% | 0.00% | – |
Q2 2018 | $1,285,000 | +19.4% | 16,725 | -20.7% | 0.00% | – |
Q1 2018 | $1,076,000 | +7.1% | 21,097 | -2.6% | 0.00% | – |
Q4 2017 | $1,005,000 | -90.3% | 21,667 | -88.7% | 0.00% | -100.0% |
Q3 2017 | $10,321,000 | -14.7% | 191,204 | -1.8% | 0.00% | -33.3% |
Q2 2017 | $12,095,000 | -26.8% | 194,740 | -20.1% | 0.00% | -25.0% |
Q1 2017 | $16,512,000 | -8.1% | 243,606 | -4.7% | 0.00% | 0.0% |
Q4 2016 | $17,975,000 | -10.0% | 255,645 | -9.2% | 0.00% | -20.0% |
Q3 2016 | $19,974,000 | +55.1% | 281,549 | +6.9% | 0.01% | +66.7% |
Q2 2016 | $12,881,000 | -21.0% | 263,337 | +2.3% | 0.00% | -25.0% |
Q1 2016 | $16,305,000 | -40.1% | 257,531 | +6.1% | 0.00% | -42.9% |
Q4 2015 | $27,221,000 | +55.1% | 242,668 | +33.2% | 0.01% | +40.0% |
Q3 2015 | $17,550,000 | +26.1% | 182,226 | +34.1% | 0.01% | +66.7% |
Q2 2015 | $13,914,000 | +8.6% | 135,898 | -34.2% | 0.00% | 0.0% |
Q1 2015 | $12,817,000 | +45.1% | 206,430 | +2.6% | 0.00% | +50.0% |
Q4 2014 | $8,832,000 | -20.2% | 201,293 | +3.0% | 0.00% | -33.3% |
Q3 2014 | $11,065,000 | +24.5% | 195,500 | -1.3% | 0.00% | +50.0% |
Q2 2014 | $8,891,000 | +0.2% | 198,075 | +9.1% | 0.00% | 0.0% |
Q1 2014 | $8,877,000 | – | 181,560 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |